Gross margin increased by 170 basis points to 37.7% driven by pricing power.
Reported a net loss of $4.8 million for the first quarter.
Incurred $2.0 million in restructuring charges for facility relocation and workforce reorganization.
High leverage with a strict 5.0x Total Net Leverage Ratio covenant on the term loan.
The Q1 2026 filing reveals a company at a critical crossroads, balancing impressive short-term margin recovery against long-term debt and operational risks. While the top-line growth and gross margin expansion suggest that management's pricing strategies are working, the net loss of $4.8 million and the reliance on non-GAAP Adjusted EBITDA highlight the ongoing struggle to achieve GAAP profitability. The successful migration to the Hagerstown facility and the execution of Project Concord are the primary variables that will determine if the company can lower its break-even point. Ultimately, the investment case hinges on the timing of cash flows. If the company can realize the Hagerstown efficiencies and potentially secure tariff refunds before its debt covenants become an existential threat, the bull case for a structural turnaround is viable. However, the thin liquidity cushion and the looming impact of higher-cost inventory create a narrow margin for error, making the stock a high-beta play on operational execution and regulatory outcomes.